A
Adnan Tufail
Researcher at Moorfields Eye Hospital
Publications - 274
Citations - 12126
Adnan Tufail is an academic researcher from Moorfields Eye Hospital. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 52, co-authored 256 publications receiving 9323 citations. Previous affiliations of Adnan Tufail include UCL Institute of Ophthalmology & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Clinically applicable deep learning for diagnosis and referral in retinal disease
Jeffrey De Fauw,Joseph R. Ledsam,Bernardino Romera-Paredes,Stanislav Nikolov,Nenad Tomasev,Sam Blackwell,Harry Askham,Xavier Glorot,Brendan O'Donoghue,Daniel Visentin,George van den Driessche,Balaji Lakshminarayanan,Clemens Meyer,Faith Mackinder,Simon Bouton,Kareem Ayoub,Reena Chopra,Dominic King,Alan Karthikesalingam,Cian Hughes,Rosalind Raine,Julian Hughes,Dawn A Sim,Catherine A Egan,Adnan Tufail,Hugh Montgomery,Demis Hassabis,Geraint Rees,Trevor Back,Peng T. Khaw,Mustafa Suleyman,Julien Cornebise,Pearse A. Keane,Olaf Ronneberger +33 more
TL;DR: A novel deep learning architecture performs device-independent tissue segmentation of clinical 3D retinal images followed by separate diagnostic classification that meets or exceeds human expert clinical diagnoses of retinal disease.
Journal ArticleDOI
Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration.
Lyndon da Cruz,Kate Fynes,Odysseas Georgiadis,Odysseas Georgiadis,Odysseas Georgiadis,Julie Kerby,Yvonne Hsu-Lin Luo,Yvonne Hsu-Lin Luo,Yvonne Hsu-Lin Luo,Ahmad Ahmado,Amanda J. Vernon,Julie T. Daniels,Britta Nommiste,Shazeen M Hasan,Sakina B Gooljar,Amanda-Jayne F. Carr,Anthony A. Vugler,Conor M. Ramsden,Conor M. Ramsden,Magda Bictash,Mike Fenster,Juliette Steer,Tricia Harbinson,Anna Wilbrey,Adnan Tufail,Adnan Tufail,Gang Feng,Mark Whitlock,Anthony G. Robson,Anthony G. Robson,Graham E. Holder,Graham E. Holder,Mandeep S. Sagoo,Mandeep S. Sagoo,Peter T. Loudon,Paul J. Whiting,Paul J. Whiting,Peter J. Coffey,Peter J. Coffey,Peter J. Coffey +39 more
TL;DR: This work supports the feasibility and safety of hESC-RPE patch transplantation as a regenerative strategy for AMD and presents the preclinical surgical, cell safety and tumorigenicity studies leading to trial approval.
Journal ArticleDOI
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3.
Srinivas R. Sadda,Robyn H. Guymer,Frank G. Holz,Steffen Schmitz-Valckenberg,Christine A. Curcio,Alan C Bird,Barbara A Blodi,Ferdinando Bottoni,Usha Chakravarthy,Emily Y. Chew,Karl G. Csaky,Ronald P. Danis,Monika Fleckenstein,K. Bailey Freund,Juan E. Grunwald,Carel B. Hoyng,Glenn J. Jaffe,Sandra Liakopoulos,Jordi Monés,Daniel Pauleikhoff,Philip J. Rosenfeld,David Sarraf,Richard F. Spaide,Ramin Tadayoni,Adnan Tufail,Adnan Tufail,Sebastian Wolf,Giovanni Staurenghi +27 more
TL;DR: A classification system and criteria for OCT-defined atrophy in the setting of AMD has been proposed based on an international consensus and is a more complete representation of changes that occur in AMD than can be detected using color fundus photography alone.
Journal ArticleDOI
Repeatability of Manual Subfoveal Choroidal Thickness Measurements in Healthy Subjects Using the Technique of Enhanced Depth Imaging Optical Coherence Tomography
TL;DR: A change of >32 μm was likely to exceed interobserver variability in SFCT, and future studies are required to estimate the repeatability of SFCT measurements in patients with chorioretinal pathology.
Journal ArticleDOI
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Frank G. Holz,Srinivas R. Sadda,Brandon G. Busbee,Emily Y. Chew,Paul Mitchell,Adnan Tufail,Christopher Brittain,Daniela Ferrara,Sarah Gray,Lee Honigberg,Jillian Martin,Barbara Tong,Jason S. Ehrlich,Neil M. Bressler +13 more
TL;DR: In Chroma and Spectri, the largest studies of GA conducted to date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment, and no benefit was observed across prespecified subgroups, including by complement factor I–profile biomarker.